Ligand Pharma (LGND) Tops Q1 EPS by 40c

Ligand Pharma (NASDAQ: LGND) reported Q1 EPS of $1.55, $0.40 better than the analyst estimate of $1.15. Revenue for the quarter came in at $56.2 million versus the consensus estimate of $43.02 million.

GUIDANCE:

Ligand Pharma sees FY2018 EPS of $4.85, versus the consensus of $4.67.

Ligand affirms previous guidance for 2018 revenue to be approximately $184 million, including royalties of approximately $116 million, material sales of approximately $23 million and license fees and milestones of approximately $45 million, with the potential for up to an additional $20 million in license fees and milestones. Ligand notes that with revenue of $184 million, adjusted earnings per diluted share would be approximately $4.85.

For earnings history and earnings-related data on Ligand Pharma (LGND) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Terra Innovatum Global N.V. (NKLR) Misses Q2 EPS by 12c
• Baidu slips as Q2 results miss estimates despite growth in AI cloud business